Cerebral Amyloid Angiopathy
The most likely diagnosis is cerebral amyloid angiopathy (CAA), given the patient's age (82 years), mild dementia, and MRI showing multiple lobar microbleeds in characteristic locations (frontal lobe, periventricular region, and cerebellum). 1
Diagnostic Reasoning
Why CAA is Most Likely
Multiple lobar microbleeds (≥4) are a specific biomarker for CAA, particularly when strictly lobar in distribution and <10mm in diameter, which matches this patient's MRI findings in the frontal lobe and periventricular regions 1
Age >80 years is the strongest risk factor for sporadic CAA, with incidence directly correlating with advancing age, making this the most probable diagnosis in an 82-year-old 2
Pre-existing mild dementia supports CAA as the underlying pathology, since CAA is now recognized as a significant contributor to age-related cognitive decline and progressive neurodegeneration independent of Alzheimer's pathology 3
Recent TIA history is consistent with CAA, which causes not only hemorrhagic strokes but also ischemic brain injury through CAA-related brain ischemia leading to cortical disconnection 3
The distribution pattern across multiple lobes (frontal, periventricular, cerebellar) is characteristic of CAA, which affects leptomeningeal and cortical vessels throughout the brain 2
Why Other Diagnoses Are Less Likely
Hypertensive arteriopathy typically produces deep microbleeds in basal ganglia, thalami, and brainstem rather than the lobar distribution seen here, though the blood pressure of 152/86 mmHg indicates some hypertensive contribution 4, 5
Infectious vasculitis would present with fever (patient is afebrile), systemic inflammatory markers, and typically shows vessel wall enhancement on contrast MRI, none of which are described 6
Cerebral venous sinus thrombosis presents acutely with severe headache, seizures, and shows characteristic venous infarction patterns with hemorrhagic transformation on imaging, not multiple chronic microbleeds 7
Clinical Significance and Management Implications
Immediate Diagnostic Confirmation
MRI without contrast using T2 GRE or SWI sequences is the diagnostic study of choice* to confirm CAA by detecting microhemorrhages and superficial cortical siderosis that CT cannot visualize 1
Look specifically for superficial cortical siderosis, which is highly specific for CAA and represents hemosiderin deposition in the subarachnoid space 1
3T MRI is preferred over 1.5T due to higher sensitivity for detecting microhemorrhages 1
Critical Management Decisions
Avoid anticoagulation given the high risk of intracerebral hemorrhage in CAA patients, even if atrial fibrillation develops; consider left atrial appendage closure as a nonpharmacological alternative 8
Target blood pressure <120 mmHg systolic through intensive control, as this reduces mortality, cerebrovascular events, and dementia progression, with a linear relationship between lower BP and reduced vascular cognitive impairment risk down to at least 100/70 mmHg 9, 10
Initiate statin therapy for LDL-cholesterol reduction unless contraindicated, as part of comprehensive vascular risk factor management 10
Cognitive Management
Consider donepezil 10mg daily as it ranks first for improving cognition in vascular cognitive impairment, though it has the most side effects; galantamine is second in both efficacy and tolerability 9, 11
Memantine may provide small improvements in vascular dementia and can be considered as alternative or adjunct therapy 9, 11
Perform formal cognitive testing focusing on executive function and processing speed, as these domains are most affected by white matter changes associated with CAA 9
Common Pitfalls to Avoid
Do not assume all cognitive deficits are purely vascular; mixed Alzheimer's disease pathology is common (up to 38% prevalence) and probability increases with age, so consider amyloid PET imaging if diagnostic uncertainty exists 10
Do not delay aggressive vascular risk factor modification while awaiting symptom progression; proactive blood pressure control is essential for preventing further brain injury and recurrent intracerebral hemorrhage 9
Watch for inflammatory CAA (CAA-related inflammation or ABRA), which presents with subacute encephalopathy, seizures, or focal deficits and often responds to immunosuppressive treatment; this would show leptomeningeal, parenchymal, or vessel wall enhancement on post-contrast MRI 6, 12
Recognize that CAA causes brain atrophy and cognitive decline through mechanisms beyond hemorrhagic stroke, including ischemia, cortical disconnection, and BBB dysfunction 3, 5